Page 256 - 2021_04-Haematologica-web

Letters to the Editor
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma
Along with the progression of bone disease, the bone marrow (BM) microenvironment is skewed in multiple myeloma (MM). This underlies the unique pathophysiol- ogy of MM, and confers aggressiveness and drug resist-
ance. Receptor activator of NF-κB ligand (RANKL), a crit- ical mediator of osteoclastogenesis, is upregulated to extensively enhance osteoclastogenesis and bone resorp- tion in MM. Importantly, activated osteoclasts (OC) in turn enhance glycolysis in MM cells and thereby MM cell proliferation, leading to the formation of a vicious cycle between MM tumor expansion and osteoclastic bone destruction.1-3 OC should therefore be targeted to improve treatment efficacy, especially in MM cells
AB
C
D
EF
1172
haematologica | 2021; 106(4)